Related Experiment Video
Updated: Feb 6, 2026

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
Published on: May 21, 2018
Synergistic Effect of Simvastatin and Romidepsin on Gamma-globin Gene Induction
Hussain Habibi1, Amir Atashi1, Saeid Abroun1
1Department of Hematology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Insights
Combining Simvastatin and Romidepsin significantly boosts fetal hemoglobin (HbF) production. This dual therapy may offer a new treatment for beta-thalassemia and sickle cell disease (SCD) by reactivating gamma-globin genes.
Area of Science:
- Hematology
- Pharmacology
- Genetics
Background:
- Beta-thalassemia and sickle cell disease (SCD) are inherited hemoglobinopathies.
- Gamma-globin gene reactivation can alleviate disease symptoms.
- Fetal hemoglobin (HbF) induction is a therapeutic strategy for these disorders.
Purpose of the Study:
- To investigate the synergistic effects of Simvastatin (SIM) and Romidepsin (ROM) in inducing fetal hemoglobin (HbF).
- To evaluate SIM as a BCL11a inhibitor and ROM as a HDAC inhibitor for HbF induction.
Main Methods:
- CD34+ cells were isolated from cord blood samples.
- Cells were cultured in erythroid differentiation medium with SIM and ROM.
- Gamma-globin, BCL11a, and HDAC gene expression were analyzed using real-time PCR and immunocytochemistry.
Main Results:
- Combination therapy with SIM and ROM significantly increased Gamma-globin gene expression.
- The drug combination led to a 3.09-fold increase in HbF production compared to controls.
- SIM inhibited BCL11a expression, and ROM inhibited HDAC1 expression, key regulators of HbF.
Conclusions:
- Combined SIM and ROM therapy shows potential for ameliorating clinical manifestations of beta-thalassemia and SCD.
- This combination may reduce side effects and decrease the need for blood transfusions.
- Further research into this synergistic approach is warranted for hemoglobinopathy treatment.
Objective:
Hemoglobinopathies such as beta-thalassemia and sickle cell disease (SCD) are inherited disorders that are caused by mutations in beta-globin chain. Gamma-globin gene reactivation can ameliorate clinical manifestations of betathalassemia and SCD. Drugs that induce fetal hemoglobin (HbF) can be promising tools for treatment of beta-thalassemia and SCD patients. Recently, it has been shown that Simvastatin (SIM) and Romidepsin (ROM) induce HbF. SIM is a BCL11a inhibitor and ROM is a HDAC inhibitor and both of these drugs are Food and Drug Administration (FDA)-approved for hypercholesterolemia and cutaneous T-cell lymphoma respectively. Our aim was to evaluate the synergistic effects of these drugs in inducing HbF.
Materials And Methods:
In our experimental study, we isolated CD34+ cells from five cord blood samples that were cultured in erythroid differentiation medium containing ROM and Simvastatin. Then Gamma-globin, BCL11a and HDAC gene expression were evaluated on the 7th and 14th day of erythroid differentiation by real-time polymerase chain reaction (PCR) and immunocytochemistry.
Results:
Our results showed that combination of SIM and ROM significantly increased Gamma-globin gene expression and inhibit BCL11a and HDAC expression compared to results of using each of them alone. SIM and ROM lead to 3.09- fold increase in HbF production compared to the control group. Also, SIM inhibited BCL11a expression (0.065-fold) and ROM inhibited HDAC1 expression (0.47-fold) as two important inhibitors of HbF production after birth.
Conclusion:
We propose combination therapy of these drugs may be ameliorate clinical manifestation in beta-thalassemia and SCD with at least side effects and reduce the need for blood transfusion.
Related Concept Videos
Combinatorial Gene Control
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
Induction
A...
Self-Inductance
Consider a circuit connected to an AC source. As the current varies with time, the magnetic flux through the circuit correspondingly changes. Faraday's law tells us that an emf would...
Mutual Inductance
When two circuits carrying time-varying currents are close to one another, the magnetic flux through each circuit varies because of the changing current in the other circuit. Consequently, an emf is induced in each circuit by the changing current in the other. Therefore, this type of emf is called...
Inductive Reasoning
Inductive reasoning is common in descriptive science. A life scientist makes observations and records them. This data can be qualitative or...
Gene Flow

